Table 1.
Univariate and multivariate Cox regression analysis of the gene signature and disease-free survival of NSCLC patients
| Variables | Patients (N) |
Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| GSE31210 | ||||||
| Age | ≤ 65/> 65 | 176/50 | 1.89 (1.12–3.18) | 1.70E−02 | 2.36 (1.37–4.04) | 1.83E−03 |
| Gender | Female/male | 121/105 | 1.27 (0.78–2.07) | 3.38E−01 | ||
| ALK fusion | +/− | 215/11 | 0.74 (0.18–3.02) | 6.73E−01 | ||
| EGFR mutation | +/− | 99/127 | 0.60 (0.37–0.98) | 4.29E−02 | 1.98 (0.88–4.47) | 1.00E−01 |
| KRAS mutation | +/− | 206/20 | 0.98 (0.42–2.26) | 9.56E−01 | ||
| Triple negative | No/yes | 158/68 | 1.87 (1.14–3.08) | 1.39E−02 | 2.91 (1.30–6.54) | 9.71E−03 |
| Myc copy | Low/high | 207/17 | 1.04 (0.42–2.59) | 9.33E−01 | ||
| Stage | I/II | 168/58 | 3.16 (1.92–5.21) | 6.09E−06 | 2.77 (1.63–4.71) | 1.62E−04 |
| Smoking | No/yes | 115/111 | 1.33 (0.82–2.18) | 2.52E−01 | ||
| Risk score | Low/high | 123/103 | 3.26 (1.92–5.53) | 1.24E−05 | 3.10 (1.77–5.41) | 7.17E−05 |
| GSE37745 | ||||||
| Age | ≤ 65/> 65 | 45/51 | 0.89 (0.50–1.55) | 6.70E−01 | ||
| Gender | Female/male | 46/50 | 1.01 (0.58–1.78) | 9.60E−01 | ||
| Stage | I/II | 63/18 | 1.13 (0.54–2.38) | 7.45E−01 | ||
| Stage | I/III | 63/14 | 1.78 (0.81–3.91) | 1.48E−01 | ||
| Stage | I/IV | 63/1 | 5.71 (0.75–43.63) | 9.32E−02 | ||
| Histological type | Adeno/large | 53/13 | 1.05 (0.46–2.42) | 9.08E−01 | ||
| Histological type | Adeno/squamous | 53/30 | 1.12 (0.60–2.10) | 7.17E−01 | ||
| WHO performance status | 0/1 | 54/32 | 2.21 (1.21–4.03) | 1.02E−02 | 2.43 (1.32–4.47) | 4.31E−03 |
| WHO performance status | 0/2 | 54/6 | 1.04 (0.25–4.42) | 9.52E−01 | 1.12 (0.26–4.75) | 8.77E−01 |
| WHO performance status | 0/3 | 54/4 | 1.66 (0.50–5.53) | 4.08E−01 | 1.62 (0.49–5.38) | 4.34E−01 |
| Risk score | Low/high | 46/50 | 2.31 (1.27–4.21) | 6.08E−03 | 2.49 (1.36–4.55) | 3.10E−03 |
| GSE50081 | ||||||
| Age | ≤ 65/> 65 | 59/118 | 1.24 (0.69–2.24) | 4.77E−01 | ||
| Gender | Female/male | 81/96 | 1.68 (0.95–2.99) | 7.59E−02 | ||
| Stage | I/II | 124/53 | 1.87 (1.06–3.28) | 3.03E−02 | 1.71 (0.97–3.01) | 6.30E−02 |
| Histological type | Adeno/large | 124/7 | 1.04 (0.25–4.31) | 9.59E−01 | ||
| Histological type | Adeno/squamous | 124/42 | 0.73 (0.10–5.36) | 7.61E−01 | ||
| Histological type | Adeno/other | 124/4 | 0.74 (0.38–1.45) | 3.79E−01 | ||
| Smoking | No/yes | 24/133 | 0.70 (0.35–1.40) | 3.14E−01 | ||
| Risk score | Low/high | 83/94 | 2.42 (1.33–4.43) | 4.02E−03 | 2.30 (1.26–4.22) | 6.97E−03 |
| All patients | ||||||
| Age | ≤ 65/> 65 | 280/219 | 1.36 (1.00–1.84) | 5.04E−02 | ||
| Gender | Female/male | 248/251 | 1.31 (0.96–1.78) | 8.51E−02 | ||
| Stage | I/II | 355/129 | 2.05 (1.47–2.85) | 2.02E−05 | 1.72 (1.23–2.40) | 1.50E−03 |
| Stage | I/III | 355/14 | 3.45 (1.68–7.11) | 7.74E−04 | 2.62 (1.27–5.43) | 9.41E−03 |
| Stage | I/IV | 355/1 | 22.26 (3.01–164.44) | 2.36E−03 | 14.79 (2.00–109.7) | 8.40E−03 |
| Histological type | Adeno/large | 403/20 | 1.48 (0.75–2.93) | 2.61E−01 | ||
| Histological type | Adeno/squamous | 403/72 | 0.76 (0.11–5.44) | 7.85E−01 | ||
| Histological type | Adeno/other | 403/4 | 1.17 (0.77–1.78) | 4.52E−01 | ||
| Risk score | Low/high | 252/247 | 2.7 (1.94–3.76) | 4.16E−09 | 2.39 (1.70–3.35) | 4.47E−07 |
HR: hazard ratio; CI: confidence interval; Adeno: adenocarcinoma; Large: large cell carcinoma; Squamous: squamous cell carcinoma